Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Milk protein powder is a therapeutic agent used in an oral immunotherapy (OIT) protocol developed by the Children's Hospital of Philadelphia (CHOP) for the treatment of IgE-mediated cow's milk allergy. The powder contains cow's milk proteins, such as casein and beta-lactoglobulin, and is administered in gradually increasing doses to children aged 6 to 17 years. The goal of the treatment is to induce desensitization, thereby increasing the threshold for allergic reactions and potentially allowing for the safe consumption of milk. This approach targets the immune system's IgE-mediated response to milk allergens through gradual exposure, which modulates the allergic response over time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on milk protein powder.